Gufic Biosciences Limited has informed the Exchange about press release dated 11-Apr-2022 titled Gufic receives permission from CDSCO to manufacture and sale Isavuconazonium Sulfate API and Finished formulation Isavuconazole for Injection 200 mg/vial